Collegium Pharmaceutical, Inc.

NasdaqGS:COLL Voorraadrapport

Marktkapitalisatie: US$966.2m

Collegium Pharmaceutical Balans Gezondheid

Financiële gezondheid criteriumcontroles 2/6

Collegium Pharmaceutical heeft een totaal eigen vermogen van $234.3M en een totale schuld van $867.2M, wat de schuld-eigenvermogensverhouding op 370.2% brengt. De totale activa en totale passiva bedragen respectievelijk $1.6B en $1.4B. De EBIT Collegium Pharmaceutical is $217.7M waardoor de rentedekking 4 is. Het heeft contanten en kortetermijnbeleggingen van $145.0M.

Belangrijke informatie

370.2%

Verhouding schuld/eigen vermogen

US$867.21m

Schuld

Rente dekkingsratio4x
ContantUS$144.96m
AandelenUS$234.28m
Totaal verplichtingenUS$1.40b
Totaal activaUS$1.64b

Recente financiële gezondheidsupdates

Recent updates

Shareholders Can Be Confident That Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are High Quality

Nov 14
Shareholders Can Be Confident That Collegium Pharmaceutical's (NASDAQ:COLL) Earnings Are High Quality

Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Oct 28
Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Collegium Pharmaceutical: Diversifying And Growing

Aug 09

Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking

Jul 24
Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Right But Growth Is Lacking

Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly

Jun 05
Collegium Pharmaceutical (NASDAQ:COLL) Seems To Use Debt Quite Sensibly

Collegium Pharmaceutical: Some Positives From Its Quarterly 'Miss'

May 13

It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

May 10
It Looks Like Shareholders Would Probably Approve Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Package

Collegium Pharmaceutical Q4: The Beat Goes On

Feb 26

These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

Feb 24
These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well

There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Jan 05
There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues

Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Nov 12
Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Aug 09
Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Mar 10
Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?

Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Oct 18
Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?

Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet

Jun 24
Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet

Collegium Pharmaceutical: Oversold And Cheap

Jun 12

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $443.8M ) van COLL } dekken niet de korte termijn passiva ( $459.4M ).

Langlopende schulden: De kortetermijnactiva van COLL ( $443.8M ) dekken de langetermijnschulden ( $941.4M ) niet.


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 308.3% ) COLL wordt als hoog beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van COLL is de afgelopen 5 jaar gestegen van 13.6% naar 370.2%.

Schuldendekking: De schuld van COLL wordt goed gedekt door de operationele kasstroom ( 22.3% ).

Rentedekking: De rentebetalingen op de schuld van COLL worden goed gedekt door EBIT ( 4 x dekking).


Balans


Ontdek gezonde bedrijven